Journal of Hepatology最新文献

{"title":"Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era","authors":"Landon L. Chan, Anthony W.H. Chan, Terry C.F. Yip, Grace L.H. Wong, Alvin K.H. Ngai, Frankie Mo, S.H. Chok, Janet W.C. Kung, C.M. Chu, Kevin Mok, Molly S.C. Li, Vincent W.S. Wong, Stephen L. Chan","doi":"10.1016/j.jhep.2025.05.028","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.05.028","url":null,"abstract":"<h3>BACKGROUND</h3>Recurrence in patients with hepatocellular carcinoma (HCC) treated with curative surgery or ablation follows a bimodal pattern, with early recurrence peaking at 6 months to 1 year, and late recurrence peaking at 3 to 4 years. We postulate the use of antiviral therapies could reduce late recurrence due to better control of chronic inflammation.<h3>METHODS</h3>Patients with positive HBsAg and HCC (HBV-HCC) who received curative surgery or ablation from October 2000 to July 2017 were recruited from Prince of Wales Hospital in Hong Kong. The primary endpoint was recurrence-free survival (RFS). We conducted time-dependent survival analysis, 6-month and 12-month landmark analysis to evaluate the impact of antiviral therapy on overall recurrence and late recurrence, respectively. We conducted a secular trend analysis by stratifying the patients into early cohort (2001-2005) and late cohort (2011-2015), representing low and high prevalence of antiviral usage, to study changes in the hazards of recurrence.<h3>RESULTS</h3>765 patients with HBV-HCC were recruited. Median RFS was 31.1 (95%CI 26.6-39.4) months for the entire cohort. In the time-dependent survival analysis, antiviral therapy is associated with improved RFS in the univariate model (HR 0.84, 95% CI 0.84 [0.74-0.99], <em>p</em>=0.042) and a similar trend is observed in the multivariable model (HR 0.86, 95% CI 0.86 [0.72-1.03], <em>p</em>=0.106). Baseline antiviral therapy significantly improved RFS in the 6-month (HR 0.75, 95% CI 0.75 [0.59-0.96], <em>p</em>=0.019) and 12-month (HR 0.62, 95% CI 0.62 [0.47-0.82], <em>p</em>=0.001) landmark multivariable analyses. Secular trend analysis showed fading of the second peak of recurrence in the cohort with high exposure to antiviral therapy.<h3>CONCLUSION</h3>Following curative surgery or ablation, antiviral therapy against HBV is associated with reduction in late recurrence.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"4 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144252537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bile acid species as hepatic T lymphocyte response modulators – when bile acids interfere with tumor growth","authors":"David C. Trampert","doi":"10.1016/j.jhep.2025.04.022","DOIUrl":"10.1016/j.jhep.2025.04.022","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"83 2","pages":"Pages 598-600"},"PeriodicalIF":26.8,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Steatotic liver disease induces YAP/TAZ-driven cell competition that can suppress tumor initiation","authors":"Ana Algueró-Nadal, Hasse Mol, Elena Zoppolato, Weronika Kowalczyk, Leticia Sansores-García, Soheil Soheily, Hanne Hillen, Leen van Huffel, Matthias Van Haele, Marina Corral-Ibáñez, Dorothea Katharina Hoffelner, Leo A. van Grunsven, Tania Roskams, Olivier Govaere, Iván M. Moya, Georg Halder","doi":"10.1016/j.jhep.2025.06.002","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.06.002","url":null,"abstract":"<h3>Background &amp; Aims</h3>Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are leading risk factors for liver cancer. While inflammation and fibrosis are known to promote tumorigenesis in advanced MASH, it remains unclear how earlier stages of MASLD contribute to cancer initiation. Here, we investigated how steatosis alone, in the absence of significant fibrosis and inflammation, influences liver cancer development in mouse models.<h3>Methods</h3>We fed mice a Western diet to induce early-stage MASLD, characterized by steatosis and mild hepatitis without fibrosis. We triggered liver tumorigenesis by hydrodynamic tail vein injection of plasmids encoding oncogenes. We combined this with genetic manipulation of Hippo signaling and assessed tumor development by histology and single-nucleus RNA-sequencing.<h3>Results</h3>Western diet suppressed liver tumor development by promoting the elimination of tumor-initiating cells. This effect was not due to a direct impact on oncogene-expressing cells, but rather to increased competitiveness of the surrounding hepatocytes. Mechanistically, the Western diet activated the Hippo pathway effectors Yap and Taz in steatotic hepatocytes, enhancing their cellular fitness and enabling them to outcompete tumor-initiating cells. The progression to advanced MASH abrogated this tumor-suppressing mechanism thus allowing tumor development.<h3>Conclusions</h3>These findings reveal that steatotic hepatocytes in early MASLD can activate endogenous cell competition programs to suppress tumor initiation, a process that depends on Yap/Taz activity. This adds a new layer to our understanding of how fitness landscapes and cell-to-cell interactions within the tissue microenvironment shape cancer risk. It also shows that progression of chronic liver disease not only promotes tumorigenesis through effects of inflammation and fibrosis on tumor cells but also by disrupting the competitive defenses of normal surrounding cells.<h3>Impact and implications</h3>We found that early stages of steatotic liver disease (MASLD) can suppress tumor initiation in mouse models of liver cancer by triggering Yap/Taz-mediated cell competition. This reveals an unexpected tumor-suppressive role for early MASLD and highlights the importance of non-cell autonomous mechanisms during tumor initiation. Since Hippo-YAP/TAZ signaling is deregulated in many cancers, similar cell competition-based mechanisms may operate in other tissues.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"40 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144237424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: “Significant Hepatic Fat Loss after Metabolic Dysfunction-associated Steatotic Liver Disease: Beware of Misclassification as Absence of Disease” and “Risk stratification beyond fibrosis in SLD: The case for lifestyle-responsive prognostic tools”","authors":"Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong","doi":"10.1016/j.jhep.2025.05.027","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.05.027","url":null,"abstract":"No Abstract","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"10 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144237425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Presence but low detection rate of rat Hepatitis E Virus in patients in Germany 2022-2024","authors":"Lisa Jasmin Mueller, Marie Luisa Schmidt, Sandra Ciesek, Victor Max Corman","doi":"10.1016/j.jhep.2025.05.023","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.05.023","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>LJM: Formal analysis, Methodology, Validation, Writing – original draft, Writing – review &amp; editing; MLS: Formal analysis, Methodology, Validation, Writing – review &amp; editing: SC: Formal analysis, Validation, Supervision, Writing – review &amp; editing VMC: Conceptualization, Supervision, Validation, Writing – original draft, Writing – review &amp; editing; Berlin/Frankfurt/Munich Group for the Study of Rat HEV: Methodology, Resources, Validation, Writing – review &amp; editing;</section></section><section><section><h2>Data availability statement (delete if not applicable)</h2>Sequence data are openly available in NCBI Genbank</section></section><section><section><h2>Financial support</h2>This study was supported by the German Federal Ministry of Education and Research (BMBF) through the German Center for Infection Research</section></section><section><section><h2>Declaration of Competing Interest</h2>Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"43 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dissecting metabolic dysfunction- and alcohol-associated liver disease (MetALD) using proteomic and metabolomic profiles","authors":"Jun Liu, Sihao Xiao, Sile Hu, Rui Huang, Lingyan Chen, Jeremy W. Tomlinson, Jeremy F. Cobbold, Joanna M.M. Howson, Cornelia M. van Duijn","doi":"10.1016/j.jhep.2025.05.026","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.05.026","url":null,"abstract":"<h3>Background</h3>&amp; Aim, Metabolic dysfunction associated and alcohol associated liver disease (MetALD) is a poorly understood condition that bridges cardiometabolic and alcohol-related pathological characteristics. We aim to distinguish MetALD patients who share similar molecular signatures with alcohol-related liver disease (ALD) and those share signatures with metabolic dysfunction-associated steatotic liver disease (MASLD), and assess their prognostic risk for complications and mortality.<h3>Methods</h3>Our analysis involved 443,453 European participants from UK Biobank, including 34,147 with MetALD, 11,220 with ALD, and 124,034 with MASLD. We employed Elastic Net Regression to classify ALD and MASLD involving 249 plasma metabolites and/or 2,941 plasma proteins with various sensitivity analyses. We then used the selected concise model in MetALD patients to identify alcohol-predominant group (classified to ALD) and cardiometabolic-predominant group (classified to MASLD). Finally, we explored their 15-year risk of major outcomes (i.e., heart failure, myocardial infarction, stroke, cirrhosis, hepatocellular carcinoma and mortality) using Cox regression.<h3>Results</h3>The metabolome alone discriminated ALD from MASLD with an Area under the Curve (AUC) of 0.86, while the proteome alone achieved an AUC of 0.96. Adding age, sex, BMI, liver enzymes, or metabolome information did not enhance the AUC of the proteome model. A ten-protein model differentiated ALD and MASLD with an AUC of 0.93. This model identified that alcohol-predominant MetALD patients had significantly higher risks of mortality, and cirrhosis, along with elevated fibrosis scores and higher fibrosis stages, compared to cardiometabolic-predominant patients.<h3>Conclusions</h3>This study emphasizes the importance of subtyping differentiation using proteome data for personalized treatment and improved prognostic outcomes in MetALD patients.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"62 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144211508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prior Hepatitis E virus (HEV) genotype 1 infection is not protective against rat HEV infection in Mongolian gerbils","authors":"Tianxu Liu, Xinyue Yang, He Zhang, Xin Yin, Lin Wang","doi":"10.1016/j.jhep.2025.05.022","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.05.022","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Ethics committee</h2>The animal experiments were approved by the Committee of Laboratory Animal Welfare and Ethics, Peking University Health Science Center (DLASBE0020), and the Committee on the Ethics of Animal Experiments of the Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences (230713-03-GR).</section></section><section><section><h2>Authors' contributions</h2>LW supervised and designed the study. TL and XinyueY performed the experiments and collected data and samples. TL and XinyueY analysed the data. LW, TL, XinyueY, HZ and XinY drafted the manuscript. All authors have read and edited the manuscript. The authors have full editorial control of the paper and have provided their final approval for all the content.</section></section><section><section><h2>Data availability statement</h2>Sequence data used in this manuscript has been uploaded to GenBank under accession numbers PP291577, JX120573 and MF996356.</section></section><section><section><h2>Financial support</h2>This study was funded by the National Key Research and Development Program of China, Grant Number: 2023YFC2306900; National Natural Science Foundation of China, Grant Number: 82472261; Beijing Municipal Natural Science Foundation, Grant Number: L244032.</section></section><section><section><h2>Declaration of Competing Interest</h2>Nothing to declare.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"38 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144211010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer","authors":"Florian Castet, Carles Fabregat-Franco, John Bridgewater, Jin Won Kim, Margherita Rimini, Adelaida La Casta, Angela Lamarca, Minsu Kang, Francesca Salani, Alfredo Castillo, Andre Lopes, Jaewon Hyung, Lorenza Rimassa, Jorge Adeva, Daniel López-Valbuena, Míriam Basagaña-Farres, Simran Vaja, Ka Man Mak, Tian V. Tian, Andrés Muñoz, Andrea Casadei-Gardini","doi":"10.1016/j.jhep.2025.05.020","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.05.020","url":null,"abstract":"&lt;h3&gt;Background &amp; Aims&lt;/h3&gt;The use of surrogate endpoints in trials including biliary tract cancers (BTC) is growing. While this may expedite drug approval and decrease costs, it may not always correlate with an overall survival (OS) advantage. We aimed to explore the association of progression-free survival (PFS), objective response rate (ORR) and disease-control rate (DCR) with OS at the trial- and patient-level.&lt;h3&gt;Methods&lt;/h3&gt;For the trial-level analysis, we performed a systematic review of Pubmed/MEDLINE, Embase, Cochrane, &lt;span&gt;&lt;span&gt;clinicaltrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; and conference proceedings for phase II-III trials in advanced BTC. We used a weighted linear regression to measure the correlation of OS with PFS, ORR and DCR. For the patient-level analysis, we analyzed patients included in five randomized trials and three real-world datasets. The protocol is registered with PROSPERO, CRD42023398279.&lt;h3&gt;Results&lt;/h3&gt;For the trial-level analysis, we included 41 studies, involving 88 treatment arms and 7817 patients. The coefficient of determination (R&lt;sup&gt;2&lt;/sup&gt;) of the model was 0.71 (95% CI 0.56-0.86) for PFS, 0.01 (0-0.08) for ORR and 0.39 (0.14-0.64) for DCR. Predefined subgroup analysis showed consistent results. For the patient-level analysis, we included a total of 2506 patients, 783 in randomized trials (first-line 512, second-line 271) and 1723 in routine clinical care (first-line chemotherapy 773, first-line chemotherapy-durvalumab 628, second-line chemotherapy 322). Across the distinct datasets, the correlation coefficient ranged from 0.73 to 0.86 for PFS. A responder analysis found no association between response and survival.&lt;h3&gt;Conclusion&lt;/h3&gt;PFS shows a moderate correlation with OS both at the trial- and patient-level, while ORR and DCR show a low correlation. Whilst PFS is currently the best candidate surrogate marker for OS, our results highlight the need for novel endpoints in this field.&lt;h3&gt;IMPACT AND IMPLICATIONS&lt;/h3&gt;The use of validated surrogate endpoints in biliary tract cancer trials may decrease costs and improve study feasibility, particularly with agents that only target small subsets of patients or in trials that incorporate a cross-over design. A formal statistical validation of surrogacy requires patient-level and trial-level data. This is the first comprehensive analysis to incorporate novel agents (including immunotherapies and targeted agents), include patient-level data and rigorously and homogeneously extract appropriate measures of treatment effect for endpoint correlation. These results show a moderate correlation for progression-free survival both at the trial- and patient-level and a low correlation for disease-control rate and response rate. This information will aid clinicians in appropriately interpreting ","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"30 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144202230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reevaluating Feature Selection in Machine Learning-Based Radiomics for Hepatocellular Carcinoma: Bridging the Gap Between Predictive Accuracy and Biological Relevance","authors":"Yoshiyasu Takefuji","doi":"10.1016/j.jhep.2025.05.025","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.05.025","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial support</h2>This research has no fund.</section></section><section><section><h2>Authors' contributions</h2>Yoshiyasu Takefuji completed this research and wrote this article.</section></section><section><section><h2>Declaration of Competing Interest</h2>The author has no conflict of interest.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"6 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144177292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bringing genetic testing into the clinical management of people with MASLD: are we there yet?","authors":"Luca Valenti, Hannes Hagström","doi":"10.1016/j.jhep.2025.05.016","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.05.016","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors’ contributions</h2>HH: Writing and editing. LV: Writing and editing.</section></section><section><section><h2>Financial support</h2>LV was supported by Italian Ministry of Health (Ministero della Salute), Ricerca Finalizzata 2021 RF-2021-12373889, Italian Ministry of Health, Ricerca Finalizzata PNRR 2022 “RATIONAL” PNRR-MAD-2022-12375656; The European Union, H2020-ICT-2018-20/H2020-ICT-2020-2 under grant agreement No. 101016726 - REVEAL, HORIZON-MISS-2021-CANCER-02-03 “Genial” under grant agreement “101096312”; Italian ministry of Research (MUR) PNRR – M4 - C2 “ASSET”; PRIN 2022 MUR: “DEFENDER”.HH: Support from the Swedish</section></section><section><section><h2>Declaration of Competing Interest</h2>HHs institutions have received research funding from Astra Zeneca, EchoSens, Gilead, Intercept, MSD, Novo Nordisk, Takeda and Pfizer. He has served as consultant, speaker or on advisory boards for Astra Zeneca, Bristol Myers-Squibb, Echosens, Ipsen, MSD and Novo Nordisk and has been part of hepatic events adjudication committees for Arrowhead, Boehringer Ingelheim, KOWA and Jazz Pharma.LV reports speaking fees from: Viatris, Novo Nordisk, GSK; consulting for: Novo Nordisk, Pfizer, Boehringer</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"48 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}